Redeye: XVIVO - A major challenge triggers a major opportunity
Refinitiv閱讀少於1分鐘
Q2 reveals an unusual period of a significant slowdown for the US lung business. Apart from the surprising magnitude it also comes with a limited near-term transparency. This is a major surprise for both XVIVO, investors and some important customers. Despite a slow Q3 period we regard this as a very unusual investment opportunity ahead of normalised growth, demand and increasing launch support after 2026.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
登入或建立一個永久免費帳戶來閱讀此新聞